Navigation Links
DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
Date:8/6/2012

REMOXY, POSIDUR, ELADUR, TRANSDUR-Sufentanil and Relday are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement The statements in this press release regarding the potential bioavailability studies for REMOXY, potential regulatory meetings and submissions for REMOXY and POSIDUR, anticipated clinical trials (including timing and results) for Relday and our other drug candidates, the potential benefits and uses of our drug candidates, collaborations with third parties and potential business development activities are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of adverse decisions by regulatory agencies, including rejection of meeting requests, requests for additional information or product non-approval, delays and additional costs due to requirements imposed by regulatory agencies, potential adverse effects arising from the testing or use of our drug candidates, the potential failure of our clinical trials to meet their intended endpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and
'/>"/>

SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
6. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
7. Luminex Corporation Reports First Quarter 2012 Results
8. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
9. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
10. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- BioElectronics Corporation (OTC Pink: BIEL), maker of consumer medical ... J. Whelan , President will be interviewed by ... 9am EDT on Wednesday, August 5 th .  To ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. Whelan is ... flagship product, ActiPatch Therapy, is achieving in the UK.  ...
(Date:8/3/2015)... , Aug. 3, 2015  Charleston Laboratories, ... of its second clinical development program with a ... CL-H1T.  CL-H1T contains fast-dissolving promethazine ... developed as a treatment for migraine headache pain ... "Many patients with migraine headaches also suffer ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Encision Inc. (PK:ECIA), ... prevents dangerous stray electrosurgical burns in minimally invasive surgery, ... quarter that ended June 30, 2015. The ... a quarterly net loss of $213 thousand, or $(0.02) ... $2.476 million for a net loss of $202 thousand, ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... Association for the Study of the ... Liver Annual Meeting -, SAN ... its Phase 2 study of its lead,compound, MitoQ(R) (mitoquinone) in liver disease. ... the Study of the Liver,(EASL) Annual Meeting, being held April 23 - ...
... VALENCIA, Calif., April 10 MannKind,Corporation (Nasdaq: ... to,the announcement by Pfizer Inc. that over the ... 4,740 patients treated with Exubera developed lung,cancer, although ... to,determine whether this observation was related to Exubera. ...
Cached Medicine Technology:Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R) 2MannKind Addresses Pfizer's Announcement Regarding Exubera 2MannKind Addresses Pfizer's Announcement Regarding Exubera 3
(Date:8/3/2015)... ... ... A July 9 article from USA Today has revealed a ... American Dental Association. According to a study by the American Dental Association, from 2000 ... single year to 2.2 million a year. Dentists and ADA officials all point to ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director of ... The new facility is licensed under Dignity Health Arizona General Hospital , ... an excellent leader and will ensure our new freestanding emergency room delivers the highest ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Foot ... of a new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region ... ankle medicine. FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is ...
(Date:8/3/2015)... Louisville, KY (PRWEB) , ... August 03, 2015 , ... ... suffer from lower back pain at least once in their lives. Often time, low ... bulges. Until recently, disc herniations could only be managed clinically with powerful pain medication ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... and connective tissues of a woman’s pelvic organs (uterus, bladder, and bowel) ... heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the aging ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2
... a statement released by Ranbaxy Pharmaceuticals Inc (RPI), they ... Award // from Wal-Mart, the largest chain store in ... of 2005. Wal-Mart Stores is a global company with ... stores and wholesale clubs across 10 countries. , ...
... cells that are responsible for causing epileptic seizures // ... of Medicine have identified glutamate receptor cells in the ... of glutamate when there is brain action that’s associated ... that will affect the protective glutamate receptors in increasing ...
... University of Michigan, who had long earlier published their findings ... ADHD, have come up with the results from the next ... the two. ,The follow up data of the ... who had snored regularly through their childhood are four times ...
... Cancer Institute and collaborating institutions have found sections of ... genes may lurk. , ,In a study ... Research, the researchers used single nucleotide polymorphism (SNP) array ... genes, to identify regions of chromosomes where genes were ...
... Vaccines for prophylaxis are well known. Famous vaccines include ... etc.; Therapeutic vaccines to cure a condition are more ... include the ones against HIV and hepatitis. The therapeutic ... combat an infectious agent, such as a virus. Now ...
... Statins are known to successfully treat atherosclerosis, the narrowing ... whether the drugs could also treat a similar condition ... valve in the heart. , ,According to a ... high doses of cholesterol-lowering drugs actually fail to treat ...
Cached Medicine News:Health News:Possible location of lung cancer genes found 2Health News:Understanding Chronic Infections May Help in Developing Therapeutic Vaccines 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: